title: [Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin-fluorouracil on the 4th day of the therapeutic regimen].
abstract: The aim of this study was to determine the value of haematological counts at the 4th day of a chemotherapy cycle, in order to foresee neutro and/or thrombocytopenia during the same chemotherapy cycle. One hundred and ten cycles of chemotherapeutic regimens with carboplatin (400 mg/m2, dl) and 5-fluorouracile (1 g/m2/d, by iv continuous infusion for 96 hours) every 3 weeks, were analyzed for 42 patients with locally advanced but non metastatic squamous cell carcinoma of head and neck, without prior chemotherapy. Lymphocyte counts were significantly decreased at the 4th day but normalized at the 8th day (P < 10(-6)). Decreases of lymphocyte and neutrophil counts at the 4th day were significantly correlated to grade > 2 neutropenia. The positive predictive value of lymphocyte or neutrophil counts is about 50% for some cut-off values but not high enough, with the schedule of chemotherapy in our study, to justify the systematic prophylactic therapy with haematopoietic growth factors.
authors.affiliation: Centre Oscar-Lambret, Lille, France.
authors.forename: P
authors.initials: P
authors.lastname: Cappelaere
authors.forename: C
authors.initials: C
authors.lastname: Fournier
authors.forename: F
authors.initials: F
authors.lastname: Rolland
authors.forename: L
authors.initials: L
authors.lastname: Meeus
authors.forename: C
authors.initials: C
authors.lastname: Domenge
authors.forename: I
authors.initials: I
authors.lastname: Krakowski
authors.forename: C
authors.initials: C
authors.lastname: De Gislain
authors.forename: J
authors.initials: J
authors.lastname: Chauvergne
authors.forename: F
authors.initials: F
authors.lastname: Dufour-Esquerre
authors.forename: J M
authors.initials: JM
authors.lastname: Pion
authors.forename: B
authors.initials: B
authors.lastname: Hecquet
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001772:Blood Cell Count / Q000187:drug effects*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects*; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D016190:Carboplatin; D005472:Fluorouracil